Glucagon-like peptide-1 receptor agonists and pancreatitis: A reconcilable divorce.
Where this comes from
- Record sourced from PubMed, PMID 40750324.
- Also identified by DOI 10.3949/ccjm.92a.24113.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Early clinical trials suggested that patients treated with glucagon-like peptide-1 (GLP-1) receptor agonists had a slightly increased risk of acute pancreatitis. Consequently, clinicians have avoided using GLP-1 receptor agonists in patients with a history of acute pancreatitis. However, recent large meta-analyses of clinical trial data do not support a class-wide risk. Denying these valuable therapeutic medications to patients with a history of pancreatitis seems unwarranted.
Medical subject headings
- Pancreatitis
- Glucagon-Like Peptide-1 Receptor Agonists
- Hypoglycemic Agents
- Diabetes Mellitus, Type 2